GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gujarat Themis Biosyn Ltd (BOM:506879) » Definitions » Debt-to-Revenue

Gujarat Themis Biosyn (BOM:506879) Debt-to-Revenue : 0.02 (As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Gujarat Themis Biosyn Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Gujarat Themis Biosyn's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹18 Mil. Gujarat Themis Biosyn's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₹16 Mil. Gujarat Themis Biosyn's annualized Revenue for the quarter that ended in Sep. 2024 was ₹1,389 Mil. Gujarat Themis Biosyn's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.02.


Gujarat Themis Biosyn Debt-to-Revenue Historical Data

The historical data trend for Gujarat Themis Biosyn's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gujarat Themis Biosyn Debt-to-Revenue Chart

Gujarat Themis Biosyn Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.05 0.01 - 0.02

Gujarat Themis Biosyn Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 - 0.02 - 0.02

Competitive Comparison of Gujarat Themis Biosyn's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Themis Biosyn's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gujarat Themis Biosyn's Debt-to-Revenue falls into.



Gujarat Themis Biosyn Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Gujarat Themis Biosyn's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(15.437 + 12.247) / 1698.081
=0.02

Gujarat Themis Biosyn's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(18.225 + 15.74) / 1388.66
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Gujarat Themis Biosyn Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gujarat Themis Biosyn's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gujarat Themis Biosyn Business Description

Traded in Other Exchanges
N/A
Address
S.V Road, Themis House, 11/12 Udyog Nagar, Goregaon (West), Mumbai, MH, IND, 400104
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.

Gujarat Themis Biosyn Headlines

No Headlines